Comments on recent development regarding reactive metabolites are posted here.
Liver Toxicity: Structural Knowledge May Help Avoiding Rare Drug Adverse Events
Comments on possible links between recent observations of hepatotoxicity and reactive metabolites
27 Sep 2025 (updated 5 Oct)
Many obstacles have to be overcome before a new drug can be launched but the challenges do not stop there. The approved drug being used in many more patients than in the clinical trials, rare adverse effects (AE) are more likely to show up. Especially problematic is idiosyncratic drug induced liver injury (iDILI), which has caused licensed drugs to be withdrawn or more often be…
On Structural Alerts for Reactive Metabolites in the Recent Literature
A few glimpses from the recent literature; posted on LinkedIn on 4 May 2025. PDF available here.
Having followed the scientific literature on reactive metabolites (RM) for almost twenty years, I have noticed a shift in how and what researchers publish. Formation of RMs from drugs is important because it is the main cause of idiosyncratic drug induced liver injury (iDILI), which has terminated many drugs in clinical development, latest the GLP-1 recepto…